Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Celmods potently inhibit m-MDSC induction by targeting IL-10 and MIF in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

HNHiroaki Nagata

Discussion

Loading...

Member takes

Overview

Observational analysis reduced M-MDSC induction by targeting IL-10 and MIF in multiple myeloma, suggesting CELMoDs enhance immune response.

Key Points

  • M-MDSC induction was significantly decreased in multiple myeloma after treatment with immunomodulatory drugs.
  • Pomalidomide and CELMoDs promote anti-tumor immune responses by modulating key immunosuppressive mediators.
  • Analysis using RNA microarray gene expression profiling revealed changes in inflammatory response genes.
  • Findings highlight potential for CELMoDs in targeting MDSCs to improve outcomes in multiple myeloma.

Cite This Study

Hiroaki Nagata (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d91chttps://doi.org/10.1182/blood-2025-7447
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multistep molecular trajectory during monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells2025
  2. 2Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma2025 · 7 citations
  3. 3Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death2025
  4. 4Mezigdomide overcomes CRBN mutations emerging post IMiD therapy2025
  5. 5Pomalidomide promotes activation induced cell death of pre-activated, memory BCMA CAR-T cells in a model of high, but not low, tumor burden multiple myeloma2025 · 1 citations